Video

Dr. Jotte on the Low Rate of Screening in Lung Cancer

Robert M. Jotte, MD, PhD, medical director and co-chair of the USON Thoracic Committee at Rocky Mountain Cancer Centers, discusses the low rate of screening for lung cancer.

Robert M. Jotte, MD, PhD, medical director and co-chair of the USON Thoracic Committee at Rocky Mountain Cancer Centers, discusses the low rate of screening for lung cancer.

There are many reasons why there is such a low rate of lung cancer screening, explains Jotte. The primary reason is that the topic is not being brought up. Primary care providers are expected to address a variety of problems in a relatively short office visit, and so lung cancer screening is often overlooked. Physicians must decipher what the immediate risk to the patient is, and proceed accordingly.

In a 15-minute appointment, a patient is expected to disclose all their problems, have the physician address those problems, and take a couple minutes to discuss a risk that may never materialize. However, for the patients in whom it does materialize, it can be lifesaving, says Jotte.

Related Videos
Alan Tan, MD, genitourinary oncology and melanoma specialist, Vanderbilt-Ingram Cancer Center; associate professor, medicine, Division of Hematology Oncology, Vanderbilt University Medical Center
Zosia Piotrowska, MD, MHS, instructor, Harvard Medical School; medical oncologist, Massachusetts General Hospital
Bartosz Chmielowski, MD
Raza Hoda, MD, FASCP
Armin Ghobadi, MD, professor, medicine, Oncology, Section of Bone Marrow Transplant; clinical director, Center for Gene and Cellular Immunotherapy, Siteman Cancer Center, Washington University
Timothy S. Fenske, MD, MS
Yair Lotan, MD, professor, urology, chief, urologic oncology, Jane and John Justin Distinguished Chair in Urology, UT Southwestern Harold C. Simmons Comprehensive Cancer Center; medical director, Urology Clinic, UT Southwestern and Parkland Health and Hospital System
Roxana S. Dronca, MD, discusses the FDA’s approval of subcutaneous nivolumab across solid tumor indications.
Craig Eckfeldt, MD
Whitney Goldsberry, MD